Dr. Reddy's Laboratories launches Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.Reddy's") today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera® (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA).

The Tecfidera® brand and generic market had U.S. sales of approximately $3.8 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.

Dr. Reddy's Dimethyl Fumarate Delayed-Release Capsules are available in 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5114.05 as compared to the previous close of Rs. 5024.45. The total number of shares traded during the day was 102303 in over 8695 trades.

The stock hit an intraday high of Rs. 5150 and intraday low of 5050. The net turnover during the day was Rs. 521531405.

Tecfidera® is a trademark of Biogen.

*IQVIA Retail and Non-Retail MAT June 2020

Source : Equity Bulls

Keywords